IRIDEX (IRIX) Stock Price, News & Analysis

Company Overview

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets. Its products are used in hospitals, clinics and ophthalmology practices worldwide.

Key Stats

• Today's Range: $0.79 to $0.90
• 50-Day Range: $0.61 to $0.93
• 52-Week Range: $0.61 to $1.65
• Volume: 42,345 shs
• Average Volume: 1.10 million shs
• Market Capitalization: $14.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

IRIDEX Stock Analysis - MarketRank™

IRIDEX scored higher than 50% of companies evaluated by MarketBeat, and ranked 503rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

IRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

IRIDEX has a consensus price target of $3.00, representing about 268.3% upside from its current price of $0.81.

Amount of Analyst Coverage

IRIDEX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IRIDEX is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IRIDEX is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 3.49, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IRIDEX has recently decreased by 17.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IRIDEX does not currently pay a dividend.

Dividend Growth

IRIDEX does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.49

News Sentiment

IRIDEX has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for IRIDEX this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for IRIX on MarketBeat in the last 30 days.

MarketBeat Follows

11 people have added IRIDEX to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IRIDEX insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.60% of the stock of IRIDEX is held by insiders.

Percentage Held by Institutions

20.10% of the stock of IRIDEX is held by institutions.

Company Calendar

• Last Earnings: 8/18/2026
• Today: 10/18/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:IRIX
• CIK: 1006045
• Web: www.iridex.com
• Phone: (650) 940-4700
• Fax: 650-940-4710
• Employees: 108
• Year Founded: 1989

Price Target and Rating

• Average Price Target for IRIDEX: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +268.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.44 million
• Net Margins: -6.88%
• Pretax Margin: -6.58%
• Return on Equity: N/A
• Return on Assets: -12.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $52.67 million
• Price / Sales: 0.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -13.58

Miscellaneous

• Outstanding Shares: 17,570,000
• Free Float: 16,054,000
• Market Cap: $14.31 million
• Optionable: Optionable
• Beta: 0.67